An intrinsically labile α-helix abutting the BCL9-binding site of β-catenin is required for its inhibition by carnosic acid

Verfasser / Beitragende:
[Marc De la Roche, Trevor J. Rutherford, Deepti Gupta, Dmitry B. Veprintsev, Barbara Saxty, Stefan M. Freund, Mariann Bienz]
Ort, Verlag, Jahr:
2012
Enthalten in:
Nature Communications, 3, p. 680
Format:
Artikel (online)
ID: 528785087
LEADER caa a22 4500
001 528785087
005 20190713030951.0
007 cr unu---uuuuu
008 180924s2012 xx s 000 0 eng
024 7 0 |a 10.3929/ethz-b-000062260  |2 doi 
024 7 0 |a 10.1038/ncomms1680  |2 doi 
035 |a (ETHRESEARCH)oai:www.research-collecti.ethz.ch:20.500.11850/62260 
245 0 3 |a An intrinsically labile α-helix abutting the BCL9-binding site of β-catenin is required for its inhibition by carnosic acid  |h [Elektronische Daten]  |c [Marc De la Roche, Trevor J. Rutherford, Deepti Gupta, Dmitry B. Veprintsev, Barbara Saxty, Stefan M. Freund, Mariann Bienz] 
246 0 |a Nat Commun 
506 |a Open access  |2 ethresearch 
520 3 |a Wnt/β-catenin signalling controls development and tissue homeostasis. Moreover, activated β-catenin can be oncogenic and, notably, drives colorectal cancer. Inhibiting oncogenic β-catenin has proven a formidable challenge. Here we design a screen for small-molecule inhibitors of β-catenin's binding to its cofactor BCL9, and discover five related natural compounds, including carnosic acid from rosemary, which attenuates transcriptional β-catenin outputs in colorectal cancer cells. Evidence from NMR and analytical ultracentrifugation demonstrates that the carnosic acid response requires an intrinsically labile α-helix (H1) amino-terminally abutting the BCL9-binding site in β-catenin. Similarly, in colorectal cancer cells with hyperactive β-catenin signalling, carnosic acid targets predominantly the transcriptionally active ('oncogenic') form of β-catenin for proteasomal degradation in an H1-dependent manner. Hence, H1 is an 'Achilles' Heel' of β-catenin, which can be exploited for destabilization of oncogenic β-catenin by small molecules, providing proof-of-principle for a new strategy for developing direct inhibitors of oncogenic β-catenin. 
540 |a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported  |u http://creativecommons.org/licenses/by-nc-nd/3.0  |2 ethresearch 
700 1 |a De la Roche  |D Marc  |e joint author 
700 1 |a Rutherford  |D Trevor J.  |e joint author 
700 1 |a Gupta  |D Deepti  |e joint author 
700 1 |a Veprintsev  |D Dmitry B.  |e joint author 
700 1 |a Saxty  |D Barbara  |e joint author 
700 1 |a Freund  |D Stefan M.  |e joint author 
700 1 |a Bienz  |D Mariann  |e joint author 
773 0 |t Nature Communications  |d London : Nature Publishing Group  |g 3, p. 680  |x 2041-1723 
856 4 0 |u http://hdl.handle.net/20.500.11850/62260  |q text/html  |z WWW-Backlink auf das Repository (Open access) 
908 |D 1  |a Journal Article  |2 ethresearch 
950 |B ETHRESEARCH  |P 856  |E 40  |u http://hdl.handle.net/20.500.11850/62260  |q text/html  |z WWW-Backlink auf das Repository (Open access) 
950 |B ETHRESEARCH  |P 700  |E 1-  |a De la Roche  |D Marc  |e joint author 
950 |B ETHRESEARCH  |P 700  |E 1-  |a Rutherford  |D Trevor J.  |e joint author 
950 |B ETHRESEARCH  |P 700  |E 1-  |a Gupta  |D Deepti  |e joint author 
950 |B ETHRESEARCH  |P 700  |E 1-  |a Veprintsev  |D Dmitry B.  |e joint author 
950 |B ETHRESEARCH  |P 700  |E 1-  |a Saxty  |D Barbara  |e joint author 
950 |B ETHRESEARCH  |P 700  |E 1-  |a Freund  |D Stefan M.  |e joint author 
950 |B ETHRESEARCH  |P 700  |E 1-  |a Bienz  |D Mariann  |e joint author 
950 |B ETHRESEARCH  |P 773  |E 0-  |t Nature Communications  |d London : Nature Publishing Group  |g 3, p. 680  |x 2041-1723 
898 |a BK010053  |b XK010053  |c XK010000 
949 |B ETHRESEARCH  |F ETHRESEARCH  |b ETHRESEARCH  |j Journal Article  |c Open access